Targeting transglutaminase-2 to overcome chemoresistance in cancer cells

Drug Resistance in Cancer Cells

Volumn , Issue , 2009, Pages 95-114

  Mehta, Kapil ^a   Fok, Jansina Y ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

AKT; Apoptosis; Autophagy; Drug resistance; Focal adhesion kinase; Integrins; Metastasis; NF B; PTEN

Indexed keywords

EID: 84900182284     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-89445-4_5     Document Type: Chapter

References (102)

1. Adjei, A. A. 2006. Novel combinations based on epidermal growth factor receptor inhibition, Clin. Cancer Res. 12:4446-4450.
2. Ahn, J.-S., Kim, M.-K., Hahn, H.-H., Park, J.-H., Park, K.-H., Cho, B.-R., Park, S. B., Kim, D.-J. 2008. Tissue transglutaminase-induced down regulation of matrix metalloprotease-9. Biochem. Biophys. Res Commun. 376:743-747.
3. Akar, U., Ozpolat, B., Mehta, K., Fok, J. Y., Kondo Y., and Berestein, G. L. 2007. Tissue transglutaminase inhibits autophagy in pancreatic cancer cells. Mol. Cancer Res. 5:241-249.
4. Akimov, S. S., Krylov, D., Fleischman, L. F., and Belkin, A. M. 2000. Tissue transglutaminase is an integrin-binding adhesion coreceptor for fibronectin. J. Cell. Biol. 148:825-838.
5. Akimov, S. S., and Belkin, A. M. 2001. Cell surface tissue transglutaminase is involved in adhesion and migration of monocytic cells on fibronectin. Blood 98:1567-1576.
6. Alahari, S. K., Lee, J. W., and Julaino, R. L. 2000. Nischarin, a novel protein that interacts with the integrin a5 subunit and inhibits cell migration. J. Cell Biol. 151:1141-1154.
7. Ai, L., Kim, W. J., Demircan, B., Dyer, L. M., Bray, K. J., Skehan, R. R., Massoll, N. A., and Brown, K. D. 2008. The transglutaminase 2 gene, a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer. Carcinogenesis 29:510-518.
8. Antonyak, M. A., Miller, A. M., Jansen, J. M., Boehm, J. E., Balkman, C. E., Wakshlag, J. J., Page, R. L., Cerione, R. A. 2004. Augmentation of tissue transglutaminase expression and activation by epidermal growth factor inhibit doxorubicin-induced apoptosis in human breast cancer cells. J. Biol. Chem. 40:41461-41467.
9. Baeuerle, P. A., and Baltimore, D. 1996. NF-kB: ten years after. Cell 87:13-20.
10. Bargou, R. C., Emmerich, F., Krappmann, D., Bommert, K., Mapara, M. Y., Arnold, W., Royer, H. D., Grinstein, E., Greiner, A., Scheidereit, C., and Dorken, B. 1997. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J. Clin. Invest. 100:2961-2969.
11. Birckbichler, P. J., Bonner, R. B., Hurst, R. E., Bane, B. L., Pitha, J. V., and Hemstreet, G. P. III. 2000. Loss of tissue transglutaminase as a biomarker for prostate adenocarcinoma. Cancer. 89:412-423.
12. Bloom, R. and Kloog, Y. 2005. Tailoring Ras-pathway-inhibitor combinations for cancer therapy. Drug Resist. Updates 8:369-380.
13. Boehm, J. E., Singh, U., Combs, C., Antonyak, M. A., and Cerione, R. A. 2002. Tissue transglutaminase protects against apoptosis by modifying the tumor suppressor protein p110 Rb. J. Biol. Chem. 277:20127-20130.
14. Bohuslav, J., Chen, L. F., Kwon, H., Mu, Y., and Greene, W. C. 2004. p53 induces NF-kB activation by an IkB kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase. J. Biol. Chem. 279:26115-26125.
15. Bours, V., Dejardin, E., Goujon-Letawe, F., Merville, M. P., and Castronovo, V. 1994. The NF-kappa B transcription factor and cancer: high expression of NF-kappa B- and I kappa Brelated proteins in tumor cell lines. Biochem. Pharmacol. 47:145-149.
16. Bours, V., Bonizzi, G., Bentires-Alj, M., Bureau, F., Piette, J., Lekeux, P., and Merville. M. 2000. NF-kB activation in response to toxical and therapeutical agents: role in inflammation and cancer treatment. Toxicology 153:27-38.
17. Brown, E. J., Frazier, W. A. 2001. Integrin-associated protein (CD47) and its ligands. Trends Cell Biol. 11:130-135.
18. Broxterman H. J., and Georgopapadakou, N. H. 2005. Anticancer therapeutics: "Addictive" targets, multi-targeted drugs, new drug combinations. Drug Resist. Updat. 8:183-197.
19. Chen, J., Nikolovska-Coleska, Z., Wang, G., Qiu, S., and Wang, S. 2006. Design, synthesis, and characterization of new embelin derivatives as potent inhibitors of X-linked inhibitor of apoptosis protein. Bioorg. Med. Chem. Lett. 16:5805-5808.
20. Datta, S., Antonyak, M. A., and Cerione, R. A. 2006. Importance of Ca (2+)-dependent transamidation activity in the protection afforded by tissue transglutaminase against doxorubicin-induced apoptosis. Biochemistry 45:13163-13174
21. De Laurenzi, V., and Melino, G. 2001. Gene disruption of tissue transglutaminase. Mol. Cell. Biol. 21:148-155.
22. Demarchi, F., and Brancolini, C. 2005. Altering protein turnover in tumor cells: new opportunities for anti-cancer therapies. Drug Resist. Updat. 8:359-368.
23. Douillette, A., Bibeau-Poirier, A., Gravel, S. P., Clement, J. F., Chenard, V., Moreau, P., and Servant M. J. 2006. The proinflammatory actions of angiotensin II are dependent on p65 phosphorylation by the IkB kinase complex. J. Biol. Chem. 281:13275-13284.
24. Edinger, A. L., and Thompson, C. B. 2003. Defective autophagy leads to cancer. Cancer Cell 4:422-424.
25. Fesik, S. W. 2005. Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer 5:876-885.
26. Fesus, L., and Piacentini, M. 2002. Transglutaminase 2: an enigmatic enzyme with diverse functions. Trends Biochem. Sci. 27:534-539.
27. Filiano, A. J., Bailey, C. D., Tucholski, J., Gundemir, S., and Johnson, G. V. 2008. Transglutaminase 2 protects against ischemic insult, interacts with HIF1{beta}, and attenuates HIF1 signaling. FASEB J. 22:2662-2675.
28. Fok, J., Ekmekcioglu, S., and Mehta, K. 2006. Tissue transglutaminase expression in melanomas: a potential target for intervention. Mol. Cancer Therapeut. 5:1493-1503.
29. Gottesman, M. M., Fojo, T., and Bates, S. E. 2002. Multidrug resistance in cancer: role of ATPdependent transporters. Nat. Rev. Cancer 2:48-58.
30. Gray, M. J., Buren, G. V., Dallas, N. A., Xia, L., Wang, X., Yang, A. D., Somcio, R. J., Lin, Y. G., Lim, S., Fan, F., Mangala, L. S., Arumugam, T., Logsdon, C. D., Lopez-Berestein. G., Sood, A. K., and Ellis, L. M. 2008. Therapeutic targeting of Neurophilin-2 on colorectal carcinoma cells implanted in the murine liver. J. Natl. Cancer Inst. 100:109-120.
31. Green, S. K., Frankel, A., and Kerbel, R. S. 1999. Adhesion-dependent multicellular drug resistance. Anticancer Drug Des. 14:153-168.
32. Griffin, M., Casadio, R., and Bergamini, C. M. 2002. Transglutaminases: nature's biological glues. Biochem. J. 368:377-396.
33. Halder, J., Kamat, A. A., Landen, C. N., Jr., Han, L. Y., Lutgendorf, S. K., Lin, Y. G., Merritt, W. M., Jennings, N. B., Chavez-Reyes, A., Coleman, R. L., Gershenson, D. M., Schmandt, R., Cole, S. W., Lopez-Berestein, G., and Sood, A. K. 2006. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin. Cancer Res. 12:4916-4924.
34. Hanahan, D., Weinberg, R. A. 2000. The hallmarks of cancer. Cell 100:57-70.
35. Herman, J. F., Mangala, L. S., and Mehta, K. 2006. Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells. Oncogene 25:3049-3058.
36. Horton, T. M., Gannavarapu, A. S., Blaney, S. M., D'Argenio, D. Z., Plon, S. E., and Berg, S. L. 2006. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother. Pharmacol. 58:13-23
37. Hsia, D. A., Mitra, S. K., Hauck, C. R., Streblow, D. N., Nelson, J. A., Llic, D., Huang, S., Li, E., Nemerow, G. R., Leng, J., Spencer, K. S., Cheresh, D. A., and Schlaepfer, D. D. 2003. Differential regulation of cell motility and invasion by FAK. J. Cell Biol. 160:753-767.
38. Hwang, J. Y., Mangala, L. S., Fok, J. Y., Lin, Y. G., Merritt, W. M., Spannuth, W. A., Nick, A. M., Fiterman, D. J., Vivas-Mejia, P. E., Deavers, M. T., Coleman, R. L., Lopez-Berestein, G., Mehta, K., and Sood, A. K. 2008. Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res. 68:5849-5858.
39. Iacobuzio-Donahue, C. A., Ashfaq, R., Maitra, A., Adsay, N. V., Shen-Ong, G. L., Berg, K., Hollingsworth, M. A., Cameron, J. L., Yeo, C. J., Kern, S. E., Goggins, M., and Hruban, R. H. 2003. Highly expressed genes in pancreatic ductal adenocarcinoma: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res. 63:8614-8622.
40. Jeon, J. H., Choi, K. H., Cho, S. Y., Kim, C. W., Shin, D. M., Kwon, J. C., Song, K. Y., Park, S. C., and Kim, I. G. 2003. Transglutaminase 2 inhibits Rb binding of human papillomavirus E7 by incorporating polyamine. EMBO J. 22:5273-82.
41. Jiang, D., Ying, W., Lu, Y., Wan, J., Zhai, Y., Liu, W., Zhu, Y., Qiu, Z., Qian, X., and He, F. 2003. Identification of metastasis-associated proteins by proteomic analysis and functional exploration of interleukin-18 in metastasis. Proteomics 3:724-737.
42. Jones, R. A., Kotsakis, P., Johnson, T. S., Chau, D. Y., Ali, S., Melino, G., and Griffin, M. 2006. Matrix changes induced by transglutaminase 2 lead to inhibition of angiogenesis and tumor growth. Cell Death Differ. 13:1442-1453.
43. Joshi, S., Guleria, R., Pan, J., Di Pette, D., and Singh, U. S. 2006. Retinoic acid receptors and tissue transglutaminase mediate short-term effect of retinoic acid on migration and invasion of neuroblastoma SH-SY5Y cells. Oncogene 25:240-247.
44. Karin, M., Cao, Y., Greten, F., and Li, Z. 2002. NF-kB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2:301-310.
45. Khera, V., and Mehta, K. 1989. Tissue transglutaminase and immunologic functions of BCGelicited mouse peritoneal macrophages isolated by centrifugal elutriation. J. Leukoc. Biol. 45:434-443.
46. Kim, D. S., Park, S. S., Nam, B. H., Kim, I. H., and Kim, S. Y. 2006. Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappa B inactivation. Cancer Res. 66:10936-10943.
47. Kondo, Y., Kanzawa, T., Sawaya, R., and Kondo, S. 2005. The role of autophagy in cancer development and response to therapy. Nat. Rev. Cancer 5:726-734.
48. Kroemer, G., and Jaattela, M. 2005. Lysosomes and autophagy in cell death control. Nat. Rev. Cancer 5:886-897.
49. Lai, T. S., Slaughter, T. F., Peoples, K. A., Hettqasch, J. M., and Greenberg, C. S. 1998. Regulation of human tissue transglutaminase function by magnesium nucleotide complexes. J. Biol. Chem. 273:1776-1781
50. Landen, C. N., Jr., Chavez-Reyes, A., Bucana, C., Schmandt, R., Deavers, M. T., Lopez-Berestein. G., and Sood, A. K. 2005. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 65:6910-6918.
51. Lee, J., Kim, Y. S., Choi, D. H., Bang, M. S., Han, T. R., Joh, T. H., and Kim, S. Y. 2004. Transglutaminase 2 induces nuclear factor-kB activation via a novel pathway in BV-2 microglia. J. Biol. Chem. 279:53725-53735.
52. Lewis, T. E., Milam, T. D., Klingler, D. W., Rao, P. S., Jaggi, M., Smith, D. J., Hemstreet, G. P., and Balaji, K. C. 2005. Tissue transglutaminase interacts with proteins kinase A anchor protein 13 in prostate cancer. Urol. Oncol. 23:407-412.
53. Lorand, L., and Graham, R. M. 2003. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat. Rev. Mol. Cell. Biol. 4:140-156.
54. Mashima, T., and Tsuruo, T. 2005. Defects of the apoptotic pathway as therapeutic target against cancer. Drug Resist. Updat 8:339-343.
55. Mangala, L. S., Fok. J. Y., Zorrilla-Calancha, I. R., Verma, A., and Mehta, K. 2007. Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells. Oncogene 26:2459-2470.
56. Mann, A. P., Verma, A., Sethi, G., Manavathi, B., Wang, H., Fok, J. Y., Kunnumakkara, A. B., Kumar, R., Aggarwal, B. B., and Mehta, K., 2006. Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-{kappa}B in cancer cells: delineation of a novel pathway. Cancer Res. 66:8788-8795.
57. McLean, G. W., Carragher, N. O., Avizienyte, E., Evans, J., Brunton, V. G., and Frame, M. C. 2005. The role of focal-adhesion kinase in cancer-a new therapeutic opportunity. Nat. Rev. Cancer 5:505-515.
58. Mehta, K., Fok, J., Miller, F. R., Koul, D., and Sahin, A. A. 2004. Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin. Cancer Res. 10:8068-8076.
59. Mehta, K. 2005. Mammalian TGase: A family portrait. Prog. Exp. Tumor Res. 38:1-18.
60. Mehta, K., Fok, J. Y., and Mangala, L. S. 2006. Tissue transglutaminase: from biological glue to cell survival cues. Front Biosci. 11:173-185.
61. Mehta, K. 2008. Biological and therapeutic significance of tissue transglutaminase in pancreatic cancer. Amino Acids In press. DOI-10-1007/s00726-008-0128-4
62. Merritt, W. M., Lin, Y., G., Spannuth, W. A., Fletcher, M. S., Kamat, A. A., Han, L. Y., Landen, C. N., Jennings, N., De Geest, K., Langley, R. R., Villares, G., Sanguino, A., Lutgendorf, S. K., Lopez-Berestein, G., Bar-Eli, M. M., and Sood, A. K. 2008. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J. Natl. Cancer Inst. 100:359-372.
63. Mhaouty-Kodja, S. 2004. Ghalpha/tissue transglutaminase 2: an emerging G protein in signal transduction. Biol Cell 96:363-367.
64. Milakovic, T., Tucholski, J., McCoy, E., and Johnson, G. V. 2004. Intracellular localization and activity state of tissue transglutaminase differentially impacts cell death. J. Biol. Chem. 279:8715-8722.
65. Mishra, S., Saleh, A., Espino, P. S., Davie, J. R., and Murphy, L. J. 2006. Phosphorylation of histones by tissue transglutaminase. J. Biol. Chem. 281:5532-5538.
66. Mohan, K., Pinto, D., and Issekutz, T. B. 2003. Identification of tissue transglutaminase as a novel molecules involved in human CD8+ T cell transendothelial migration. J. Immunol. 171:3179-3186.
67. Morabito, A., De Maio, E., Di Maio, M., Normanno, N., and Perrone, F. 2006. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 11:753-764.
68. Mori, N., Fujii, M., Ikeda, S., Yamada, Y., Tomonaga, M., Ballard, D. W., and Yamamoto, N. 1999. Constitutive activation of NF-kappaB in primary adult T-cell leukemia cells. Blood 93:2360-2368.
69. Morrissey, D. V., Lockridge, J. A., Shaw, L., Blanchard, K., Jensen, K., Breen, W., Hartsough, K., Machemer, L., Radka, S., Jadhav, V., Vaish, N., Zinnen, S., Vargeese, C., Bowman, K., Shaffer, C. S., Jeffs, L. B., Judge, A., MacLachlan, I., and Polisky, B. 2005. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. 23:1002-1007.
70. Mukhopadhyay, A., Bueso-Ramos, C., Chatterjee, D., Pantazis, P., and Aggarwal, B. B. 2001. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 20:7597-7609.
71. Nanda, N., Iismaa, S. E., Owens, W., Husain, A. A., Mackay F., and Graham, R. M. 2001. Targeted inactivation of Gh/tissue transglutaminase II. J. Biol. Chem. 276:20673-20678.
72. Nawrocki, S. T., Carew, J. S., Pino, M. S., Highshaw, R. A., Dunner, K. Jr., Huang, P., Abbruzzese, J. L., and McConkey, D. J. 2005. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res. 65:11658-11666.
73. Nicholas, B., Smethurst, P., Verderio, E., Jones, R., and Griffin, M. 2003. Cross-linking of cellular proteins by tissue transglutaminase during necrotic cell death: a mechanism for maintaining tissue integrity. Biochem. J. 371:413-422.
74. Okahara, F., Ikawa, H., Kanaho, Y., and Maehama, T. 2004. Regulation of PTEN phosphorylation and stability by a tumor suppressor candidate protein. J. Biol. Chem. 79:45300-45303.
75. Owens, L. V., Xu, L., Craven, R. J., Dent, G. A., Weiner, T. M., Kornberg, L., Liu, E. T., and Cance, W. G. 1995 Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. Cancer Res. 55:2752-2755.
76. Pahl, H. L. 1999. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18:6853-6866.
77. Peng, X., Zhang, Y., Zhang, H, Graner, S., Williams, J. F., Levitt, M. L., Lokshin, A. 1999. Interaction of tissue transglutaminase with nuclear transport protein importin-alpha3. FEBS Lett. 446:35-39.
78. Pluen, A., Boucher, Y., Ramanujan, S., McKee, T. D., Gohongi, T., Di Tomaso, E., Brown, E. B., Izumi, Y., Campbell, R. B., Berk, D. A., Jain, R. K. 2001. Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc. Natl. Acad. Sci. U S A 98, 4628-4633.
79. Priglinger, S. G., Alge, C. S., Neubauer, A. S., Haritoglou, C., Kampik, A., Welge-Luessen, U. 2004. TGF-beta2-induced cell surface tissue transglutaminase increases adhesion and migration of RPE cells on fibronectin through the gelatin-binding domain. Invest. Ophthalmol Vis. Sci. 45:955-963.
80. Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., Siegel, D., Orlowski, R. Z., Kuter, D., Limentani, S. A., Lee, S., Hideshima, T., Esseltine, D. L., Kauffman, M., Adams, J., Schenkein, D. P., and Anderson, K. C. 2003. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348:2609-2617.
81. Richardson, A., and Kaye, S. B. 2005. Drug resistance in ovarian cancer: the emerging importance of gene transcription and spatio-temporal regulation of resistance. Drug Resist. Updat. 8:311-321.
82. Rodolfo, C., Mormone, E., Matarrese, P., Ciccosanti, F., Farrace, M. G., Garofano, E., Piredda, L., Fimia, G. M., Malorni, W., and Piacentini, M. 2004. Tissue Transglutaminase is a multifunctional BH3-only protein. J. Biol. Chem. 279:54783-54792.
83. Satpathy, M., Cao, L., Pincheira, R., Emerson, R., Bigsby, R., Nakshatri, H., and Matei, D. 2007 Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase. Cancer Res. 67:7194-202.
84. Schlaepfer, D. D., Hauck, C. R., and Sieg, D. J. 1999. Signaling through focal adhesion kinase. Prog. Biophys. Mol. Biol. 71:435-478.
85. Sieg, D. J., Hauck, C. R., Ilic, D., Klingbeil, C. K., Schaefer, E., Damsky, C. H., Schlaepfer, D. D. 2000. FAK integrates growth-factor and integrin signals to promote cell migration. Nat. Cell Biol. 2:249-256.
86. Sierra, A., 2005. Metastases and their microenvironment: linking pathogenesis and therapy. Drug Resist. Updat. 8:247-257.
87. Song, H., Woochul, C., Lim, S., Seo, H. S., Shim, C. Y., Park, S., Yoo, K. J., Kim, B. S., Min, B. H., Lee, H., Jang, Y., Chung, N., Hwang, K. C. 2007 Tissue transglutaminase is essential for integrin-mediated survival of bone marrow derived mesenchymal stem cells. Stem Cells 25:1431-138.
88. Stenvang, J., Kauppinen, S. 2008. MicroRNAs as targets for antisense-based therapeutics. Expert Opin Biol Ther. 8:59-81.
89. Tamura, M., Gu, J., Matsumoto, K., Aota, S., Parsons, R., and Yamada, K. M. 1998. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 280:1614-1617.
90. Torres, J., and Pulido, R. 2001. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J. Biol. Chem. 276:993-998.
91. Vazquez, F., Takahashi, Y., Rokas, M. V., Nakamura, N., and Sellers, W. R. 2001. Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J. Biol. Chem. 276:48627-48630.
92. Verderio, E. A., Johnson, T. S., and Griffin, M. 2005. Transglutaminase in wound healing and inflammation. Prog. Exp. Tumor Res. 38:89-114.
93. Verderio, E. A., Scarpellini, A., and Johnson, T. S. 2008. Novel interactions of TG2 with heparan sulfate proteoglycans: reflection on physiological implications. Amino Acids In press. DOI-10-1007/s00726-008-0134-6
94. Verma, A., Wang, H., Manavathi, B., Fok, J. Y., Mann, A. P., Kumar, R., and Mehta, K. 2006. Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis. Cancer Res. 66, 10525-10533.
95. Verma, A., and Mehta, K. 2007a. Tissue transglutaminase-mediated chemoresistance in cancer cells. Drug Res. Update. 10:144-151.
96. Verma, A., and Mehta, K. 2007b. Transglutaminase-mediated activation of nuclear transcription factor-kappaB in cancer cells: a new therapeutic opportunity. Curr. Cancer Drug Targets 7:559-565.
97. Verma, A., Guha, S., Wang, H., Fok, J. Y., Koul, D., Abbruzzese, J., Mehta, K. 2008a. Tissue transglutaminase regulates focal adhesion kinase/AKT activation by modulating PTEN expression in pancreatic cancer cells. Clin. Cancer Res. 14:1997-2005.
98. Verma, A., Guha, S., Diagaladjane, P., Kunnumakkara, A. B., Sanguino, A. M., Lopez-Berestein, G., Sood, A. K., Aggarwal, B. B., Krishnan, S., Gelovani, J. G., Mehta, K. 2008b. Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin. Cancer Res. 14:2476-2483.
99. Yuan, L., Behdad, A., Siegel, M., Khosla, C., Higashikubo, R., Rich, K. M. 2008. Tissue transglutaminase 2 expression in meningiomas. J Neurooncol. 90:125-132.
100. Wang, X., Trotman, L. C., Koppie, T., Alimonti, A., Chen, Z., Gao, Z., Wang, J., Erdjument-Bromage, H., Tempst, P., Cordon-Cardo, C., Pandolfi, P. P., Jiang, X. 2007. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 128:129-139.
101. Xu, L., and Hyne, R. O. 2007. GPR56 and TG2 - possible role in suppression of tumor growth by the microenvironment. Cell Cycle 6:160-165.
102. Yamaguchi, H., and Wang, H. G. 2006. Tissue transglutaminase serves as an inhibitor of apoptosis by cross-linking caspase 3 in thapsigargin-treated cells. Mol. Cell Biol. 26:569-579.